Table 1.
Participant characteristics at HAART initiation | 1996-2001 | 2002-2005 | 2006/2009 | P value |
---|---|---|---|---|
(n=690) | (n=189) | (n=130) | ||
Race/Ethnicity | <0.001 | |||
Hispanic (%) | 6 | 13 | 16 | |
Non-white (%) | 12 | 34 | 28 | |
Baseline education >= College (%) |
53 | 44 | 37 | <0.001 |
History of IDU(%) | 14 | 14 | 18 | 0.591 |
Chronic HBV (%) | 8 | 8 | 8 | 1.0 |
Chronic HCV (%) | 6 | 9 | 8 | 0.321 |
Age (years): Med (IQR) |
43 (39-48) |
43 (37-49) |
47 (39-53) |
0.005 |
Hyperglycemia/DM* (% of prevalence) | 8.3 | 13.2 | 18.7 | <0.001 |
Hyperlipidemia *(% of prevalence) | 58.9 | 28.1 | 35.2 | <0.001 |
CD4 count (cells/μl) Nadir: Med (IQR) |
211 (109-321) |
278 (154-373) |
310 (214-419) |
<0.001 |
CD4 count (cells/μl) Pre-HAART: Med (IQR) |
302 (164-461) |
329 (193-432) |
380 (237-527) |
<0.001 |
Pre-HAART RNA (log10 cp/mL): Med (IQR) |
4.4 (3.5-4.9) | 4.6 (3.9-5.1) | 4.5 (4.0-5.0) | 0.046 |
P values were obtained from the Fisher exact test or the Kruskal-Wallis non-parametric test, as appropriate.
Med = median, IQR = interquartile range
among pre-HAART HIV-infected person-visits by calendar periods.
Hyperglycemia/diabetes mellitus was defined as FG<110mg/dL or self-report of high blood sugar or on anti-diabetic drug Hyperlipidemia was defined as fasting total cholesterol > 210 mg/dL or self report of high total cholesterol or triglycerides or on lower-lipids medication.